The Biosimilars Price Competition and Innovation Act of 2009 (BPCIA) introduced a long-awaited, and highly-supported, abbreviated route to market for “biosimilar” and “interchangeable” biologic products. The goal was to create incentives for development
Read More...
Read the complete post at http://healthaffairs.org/blog/2014/11/17/battle-lines-drawn-over-biosimilar-application-and-patent-disclosure-process/
Posted
Nov 17 2014, 06:00 AM
by
Health Affairs Blog